갑상선암 진단 시장 규모 : 제품별, 유형별, 기술별, 최종 용도별, 예측(2024-2032년)

Global Thyroid Cancer Diagnostics Market size will expand at 5.7% CAGR from 2024 to 2032, due to increasing partnerships and collaborations alongside ongoing technological advancements. Researchers and medical professionals are improving several diagnostic methods to enhance accuracy and early detection capabilities. They are integrating advanced imaging techniques and molecular biomarkers to refine diagnostic accuracies.

Rapid advancements, such as the utilization of AI-driven algorithms are also enhancing precision through the development of next-generation diagnostic tools for treatment planning and prognostic assessment. For instance, in October 2023, Curium, a leader in nuclear medicine, and PIUR IMAGING, a pioneer in 3D ultrasound solutions, partnered to advance thyroid cancer diagnostics in Germany.

The market is segregated into product, type, technique, end-use, and region.

By product type, the thyroid cancer diagnostics market from the kits & consumables segment is estimated to rise at significant rate from 2024 to 2032 due to the need for improved accuracy and streamlined diagnostic processes. Manufacturers are developing innovative biomarker assays and imaging agents to enhance sensitivity and specificity in detecting thyroid cancer markers. In addition, developments like the integration of advanced biosensing technologies and miniaturized lab-on-a-chip devices are expanding the range of available kits and consumables for rapid and cost-effective testing.

Thyroid cancer diagnostics industry from the cancer diagnostic centers end-use segment is expected to expand from 2024 to 2032. This is owing to the increasing integration of state-of-the-art imaging technologies and molecular testing capabilities to enhance diagnostic accuracy and treatment planning. Medical professionals at these centers are refining protocols and adopting new methodologies to improve patient outcomes. The ongoing advancements in cancer diagnostic centers will further provide patients with faster, more accurate diagnoses and tailored therapeutic strategies for ensuring better management of thyroid cancer and improved overall survival rates.

Regionally, the Europe thyroid cancer diagnostics industry size is projected to depict robust growth between 2024 and 2032, propelled by regulatory support and advancements in healthcare infrastructure. Regulatory frameworks in Europe are evolving to ensure the safety and efficacy of diagnostic technologies for fostering innovation and adoption. Healthcare infrastructure improvements will also facilitate greater access to advanced diagnostic tools and expertise across the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of thyroid cancer
    • 3.2.1.2 Advancement in cancer diagnostic technologies
    • 3.2.1.3 Growing awareness through screening programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High cost of thyroid cancer diagnosis
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Kits and consumables

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Papillary carcinoma
• 6.3 Follicular carcinoma
• 6.4 Other types

Chapter 7 Market Estimates and Forecast, By Technique, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Blood test
• 7.3 Imaging
• 7.4 Biopsy
• 7.5 Other techniques

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Cancer diagnostic centers
• 8.4 Academic and research institutes
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Agilent Technologies, Inc.
• 10.3 Bio-Rad Laboratories, Inc.
• 10.4 Canon Inc.
• 10.5 Danaher Corporation
• 10.6 Esaote SPA
• 10.7 F. Hoffmann-La Roche Ltd
• 10.8 GE HealthCare
• 10.9 Hologic, Inc.
• 10.10 Illumina, Inc.
• 10.11 Koninklijke Philips N.V.
• 10.12 PerkinElmer, Inc.
• 10.13 Siemens Healthineers AG
• 10.14 Thermo Fisher Scientific Inc.
• 10.15 Veracyte, Inc.